Complications of lysinuric protein intolerance must be treated with immunosuppressive drugs

Journal of Inherited Metabolic Disease

Volumn 21, Issue 6, 1998, Pages 675-676

  Di Rocco, M ^a   Buoncompagni, A ^a   Gatton, M ^a   Picco, P ^a   Vignola, S ^a   Borrone, C ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CITRULLINE; CYCLOPHOSPHAMIDE; FERRITIN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; PREDNISONE;

AMINO ACID TRANSPORT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; NEPHRITIS; OSTEOPOROSIS; PRESCHOOL CHILD; PROTEIN INTOLERANCE; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS;

AMINO ACID METABOLISM, INBORN ERRORS; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYSINE; MALE;

EID: 0031781926     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005440802688     Document Type: Article

References (3)

1. Di Rocco M, Garibotto G, Rossi GA, et al (1993) Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr 152: 437-440.
2. Lauteala T, Sistonen P, Savontaus M, et al (1997) Lysinuric protein intolerance gene maps to the long arm of chromosome 14. Am J Hum Genet 60: 1479-1486.
3. Parsons H, Snyder F, Bowen T, Klassen J, Pinto A (1996) Immune complex disease consistent with systemic lupus erythematosus in a patient with lysinuric protein intolerance. J Inher Metab Dis 19: 627-634.